Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

INTRODUCTION: The benefits of early thromboprophylaxis in symptomatic COVID-19 outpatients remain unclear. We present the 90-day results from the randomised, open-label, parallel-group, investigator-initiated, multinational OVID phase III trial. METHODS: Outpatients aged 50 years or older with acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Voci, Davide, Götschi, Andrea, Held, Ulrike, Bingisser, Roland, Colucci, Giuseppe, Duerschmied, Daniel, Fumagalli, Riccardo M., Gerber, Bernhard, Hasse, Barbara, Keller, Dagmar I., Konstantinides, Stavros V., Mach, François, Rampini, Silvana K., Righini, Marc, Robert-Ebadi, Helia, Rosemann, Thomas, Roth-Zetzsche, Stéphanie, Sebastian, Tim, Simon, Noemi R., Spirk, David, Stortecky, Stefan, Vaisnora, Lukas, Kucher, Nils, Barco, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657896/
https://www.ncbi.nlm.nih.gov/pubmed/36396519
http://dx.doi.org/10.1016/j.thromres.2022.10.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657896/
https://www.ncbi.nlm.nih.gov/pubmed/36396519
http://dx.doi.org/10.1016/j.thromres.2022.10.021

Ejemplares similares